Evoke Pharma(US:EVOK)2025-03-26 20:04Financial Performance - Full-year revenue reached $10.2 million, a 97% year-over-year increase, exceeding the prior guidance of $10 million[8] - Q4 revenue was $3.3 million, a 24.6% increase from Q3 2024[8] - The company raised $14.3 million, ensuring Nasdaq compliance and providing a cash runway into Q1 2026[8] - Cash and cash equivalents as of December 31, 2024, were $13.6 million[47] Commercial Growth - The cumulative prescriber base grew by 46% year-over-year[8] - Fills grew by 72% year-over-year[8] - Prescriptions grew by 22% year-over-year[8] Market Position and Strategy - GIMOTI has a unique market advantage as the first and only FDA-approved nasal spray for gastroparesis[10] - The company's conversion rate in 2024 was 51% on average, with steady improvement seen over the year[20] Cost Savings - Total healthcare costs in the GIMOTI arm were $15,227 lower compared to oral metoclopramide[30] Sales and Marketing - Over 40,000 healthcare professionals were reached through email, with over 60% of targets reached via email and a ~16% email open rate[34]